Recent Press Releases

CIGNA and Merck Help Customers Better Manage Diabetes

Model Program Improves Health Outcomes and Reduces Overall CostsBlood sugar levels improved by more than 5 percentIndividuals who participated actively in CIGNA’s diabetes support program were more

Teva to Acquire Theramex, Merck KGaA's European Based Women's Health Business

Teva to Acquire Theramex, Merck KGaA's European Based Women's Health BusinessJerusalem, Israel, October 28, 2010 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and Merck Serono, a division of

Onglyza Garners a Substantial Source of its Type 2 Diabetes Patients from Januvia and Janumet

Prescribing of DPP-IV Inhibitors and GLP-1 Analogues Will Increase Over the Next Two Years, But Patient Share in Each Line of Therapy Will Remain Similar, According to a New Report from Decision

Resilient Sales and Business EPS(1) in Q3 2010

PARIS, Oct. 28 /PRNewswire-FirstCall/ --Q3 2010Change on areportedbasisChange atconstantexchange rates9 months2010Change on areportedbasisChange atconstantexchange ratesNet

Laureate Pharma Announces New Development and Manufacturing Agreement to Produce AVEO Pharmaceuticals' Antibody Therapeutic

Laureate Pharma Announces New Development and Manufacturing Agreement to Produce AVEO Pharmaceuticals' Antibody Therapeutic Laureate will manufacture AVEO's AV-201, an ErbB3-targeted monoclonal

SCM Pharma CMO unveils US expansion

UK-BASED SCM Pharma is set to open its first US office after appointing a North American based business development manager to boost the company's export revenue. After securing its first US client

Unilife Secures U.S. Government Financial Backing for the Completion of New Global Headquarters and Manufacturing Facility

Unilife Secures U.S. Government Financial Backing for the Completion of New Global Headquarters and Manufacturing Facility in York, PA Construction of state-of-the-art safety syringe manufacturing

PPD and Bend Research Enter into Collaboration to Offer Comprehensive Formulation Development

PPD and Bend Research Enter into Collaboration to Offer Comprehensive Formulation Development and Analytical Testing Capabilities WILMINGTON, N.C. & BEND, Ore., Oct 26, 2010 (BUSINESS WIRE) --

ATMI LifeSciences and Austar Announce Completion of Beijing Biopharmaceutical Manufacturing Facility

ATMI LifeSciences and Austar Announce Completion of Beijing Biopharmaceutical Manufacturing FacilityATMI Austar LifeSciences Joint Venture Expands ATMI's Global Reach; Builds Ultra-Clean Packaging

GlaxoSmithKline to Plead Guilty & Pay $750 Million to Resolve Criminal and Civil Liability Regarding Manufacturing Deficiencies

GlaxoSmithKline to Plead Guilty & Pay $750 Million to Resolve Criminal and Civil Liability Regarding Manufacturing Deficiencies at Puerto Rico PlantBOSTON - SB Pharmco Puerto Rico Inc., a

As Pharmaceutical Supply Chain Goes Global, Threat of Counterfeiting, Intellectual Property Theft and Contamination Rises, Finds

As Pharmaceutical Supply Chain Goes Global, Threat of Counterfeiting, Intellectual Property Theft and Contamination Rises, Finds New Report; New Supply Chain Management Strategies NeededNEW YORK,

VIDEO From thenewsmarket.com and AstraZeneca: AstraZeneca Announces Third Quarter and Nine Months Results 2010

NEW YORK, Oct. 28 /PRNewswire/ -- See video from AstraZeneca at:

Sanofi-aventis video Q&A: CFO Jérôme Contamine Comments on Results for Q3 2010

PARIS PARIS--(BUSINESS WIRE)-- Sanofi-aventis (Paris:SAN) (NYSE:SNY), one of the world’s largest diversified healthcare companies, reports results for the third-quarter of 2010. Jérôme Contamine,

Third Circuit Denies Mylan Motion for Interim Injunction

Company's Appeal and Case on the Merits Will ContinuePITTSBURGH, Oct. 27 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that the Third Circuit Court of Appeals denied its motion

B. Braun Voluntarily Recalls Seven Lots of Heparin Manufactured in 2008 Due to Supplier-Initiated Recall of Heparin Active Pharm

No adverse events reported and no detectable contaminate found in testing of API or finished productIRVINE, Calif., Oct. 27 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun) was recently notified by

Results From an Expanded Cohort Phase 1 Study Published in the New England Journal of Medicine Demonstrate a Majority of Patient

First-in-Class ALK Inhibitor Rapidly Advanced to Phase 3 DevelopmentNEW YORK, Oct. 27 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today the publication of data showing that 57 percent

Human Genome Sciences Announces Third Quarter 2010 Financial Results and Key Developments

- BENLYSTA® granted priority review by FDA, with PDUFA target date of December 9, 2010 - ROCKVILLE, Md.--(BUSINESS WIRE)-- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced financial results

NPS Pharmaceuticals to Report Third Quarter 2010 Financial Results

BEDMINSTER, N.J.--(BUSINESS WIRE)-- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that it will report its third quarter 2010 financial results on Tuesday, November 2, 2010 at approximately

Abbott Statement: Abbott Provides Support for Cholera Relief Efforts in Haiti

Working with Humanitarian Partner Organizations, Abbott Has Provided More Than $6.3 Million for Haiti Relief Efforts to DateABBOTT PARK, Ill., Oct. 27 /PRNewswire/ -- Abbott (NYSE: ABT) and its